Recent Quotes

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		-0.170		-0.230		-0.0600
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
KTRA	Kintara Therapeutics	1.90	0.06	3.26%		62M

Kintara Therapeutics Frequently Asked Questions

How do I buy Kintara Therapeutics (KTRA) stock?

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Who are Kintara Therapeutics's (KTRA) competitors?

Other companies in Kintara Therapeutics’s space includes: Allena Pharmaceuticals (NASDAQ:ALNA), Advaxis (NASDAQ:ADXS), Biocept (NASDAQ:BIOC), Cellectar Biosciences (NASDAQ:CLRB) and Brickell Biotech (NASDAQ:BBI).

What is the target price for Kintara Therapeutics (KTRA) stock?

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Aegis Capital on February 3, 2021. The analyst firm set a price target for 7.00 expecting KTRA to rise to within 12 months (a possible 268.42% upside). 2 analyst firms have reported ratings in the last year.

Current Stock Price for Kintara Therapeutics (KTRA)?

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $1.9 last updated Thu Jun 17 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does Kintara Therapeutics (KTRA) pay a dividend?

There are no upcoming dividends for Kintara Therapeutics.

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

Kintara Therapeutics’s Q3 earnings are confirmed for after-market on May 14, 2021.

Is Kintara Therapeutics (KTRA) going to split?

There is no upcoming split for Kintara Therapeutics.

What sector and industry does Kintara Therapeutics (KTRA) operate in?

Kintara Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.